Gold prices hold losses as US-EU trade deal eases safe‑haven demand
AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN), a global biopharmaceutical company, has announced its total number of voting rights as of April 30, 2025. In a regulatory filing with the Securities and Exchange Commission today, the company disclosed that its total issued share capital with voting rights comprises 1,550,638,452 ordinary shares, each valued at US$0.25. The company confirmed that no shares are currently held in Treasury, thus the total number of voting rights stands at 1,550,638,452.
This information is pertinent for shareholders who need to determine whether they are obliged to disclose changes in their holdings or interest in the company, as per the UK Financial Conduct Authority’s Disclosure and Transparency Rules.
AstraZeneca (NASDAQ:AZN), headquartered in Cambridge, UK, is primarily engaged in the discovery, development, and commercialization of prescription medicines, focusing on areas such as Oncology, Rare Diseases, and BioPharmaceuticals. The company operates on a global scale, with its products being available in over 125 countries.
The announcement is made in accordance with the UK Financial Conduct Authority’s Disclosure and Transparency Rule 5.6.1 and is intended to provide shareholders with the denominator for calculations related to their notification requirements concerning their interest in AstraZeneca PLC.
The company’s commitment to transparency is further underscored by its compliance with the Securities Exchange Act of 1934, as evidenced by the signing of the report by Adrian Kemp, Company Secretary of AstraZeneca PLC, on May 1, 2025. This report is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.